Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
45
BSX Quote, Financials, Valuation and Earnings
Last price:
$76.08
Seasonality move
:
4.85%
Day range:
$75.31 - $76.36
52-week range:
$72.69 - $109.50
Dividend yield:
0%
P/E ratio:
39.34x
P/S ratio:
5.68x
P/B ratio:
4.67x
Volume:
9.3M
Avg. volume:
17.9M
1-year change:
-27.59%
Market cap:
$113.1B
Revenue:
$20.1B
EPS (TTM):
$1.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.3% | 75.74% | $104.78 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.14% | 54.88% | $133.39 |
|
GMED
Globus Medical, Inc.
|
$803.3M | $1.15 | 22.74% | 70.9% | $107.17 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.8B | $2.27 | 16.41% | 10.87% | $611.82 |
|
RMD
ResMed, Inc.
|
$1.4B | $2.72 | 10.29% | 13.28% | $297.47 |
|
SYK
Stryker Corp.
|
$7.1B | $4.40 | 8.36% | 77.06% | $424.40 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp.
|
$76.28 | $104.78 | $113.1B | 39.34x | $0.00 | 0% | 5.68x |
|
ABT
Abbott Laboratories
|
$113.29 | $133.39 | $197B | 30.59x | $0.63 | 2.12% | 4.47x |
|
GMED
Globus Medical, Inc.
|
$90.15 | $107.17 | $12.1B | 29.13x | $0.00 | 0% | 4.49x |
|
ISRG
Intuitive Surgical, Inc.
|
$500.76 | $611.82 | $177.8B | 63.58x | $0.00 | 0% | 18.05x |
|
RMD
ResMed, Inc.
|
$258.91 | $297.47 | $37.7B | 25.59x | $0.60 | 0.9% | 7.04x |
|
SYK
Stryker Corp.
|
$377.32 | $424.40 | $144.4B | 44.93x | $0.88 | 0.9% | 5.81x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BSX
Boston Scientific Corp.
|
33.07% | 0.200 | 8.46% | 0.94x |
|
ABT
Abbott Laboratories
|
20.25% | 0.141 | -- | 1.12x |
|
GMED
Globus Medical, Inc.
|
2.66% | -0.409 | 1.56% | 2.23x |
|
ISRG
Intuitive Surgical, Inc.
|
0.95% | 0.941 | 0.08% | 3.73x |
|
RMD
ResMed, Inc.
|
11.83% | 0.532 | 2.42% | 2.01x |
|
SYK
Stryker Corp.
|
42.19% | 0.338 | 12.42% | 1.07x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp.
|
$3.6B | $1.2B | 8.3% | 12.55% | 22.93% | $1B |
|
ABT
Abbott Laboratories
|
$6.5B | $2.4B | 10.2% | 29.06% | 20.59% | $2.3B |
|
GMED
Globus Medical, Inc.
|
$486.7M | $134.7M | 9.44% | 10.08% | 17.51% | $209.2M |
|
ISRG
Intuitive Surgical, Inc.
|
$1.9B | $864.3M | 16.53% | 16.59% | 30.16% | $730M |
|
RMD
ResMed, Inc.
|
$867M | $500.3M | 22.22% | 25.44% | 35.16% | $305.2M |
|
SYK
Stryker Corp.
|
$4.5B | $2B | 8.59% | 15.17% | 27.74% | $1.9B |
Boston Scientific Corp. vs. Competitors
-
Which has Higher Returns BSX or ABT?
Abbott Laboratories has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 15.5%. Boston Scientific Corp.'s return on equity of 12.55% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.68.5% $0.45 $36.4B ABTAbbott Laboratories57.09% $1.02 $64.2B -
What do Analysts Say About BSX or ABT?
Boston Scientific Corp. has a consensus price target of $104.78, signalling upside risk potential of 37.36%. On the other hand Abbott Laboratories has an analysts' consensus of $133.39 which suggests that it could grow by 17.74%. Given that Boston Scientific Corp. has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific Corp. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.25 0 0 ABTAbbott Laboratories16 7 0 -
Is BSX or ABT More Risky?
Boston Scientific Corp. has a beta of 0.666, which suggesting that the stock is 33.441% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.138%.
-
Which is a Better Dividend Stock BSX or ABT?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.12% to investors and pays a quarterly dividend of $0.63 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.34% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BSX or ABT?
Boston Scientific Corp. quarterly revenues are $5.3B, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Boston Scientific Corp.'s net income of $670M is lower than Abbott Laboratories's net income of $1.8B. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 39.34x while Abbott Laboratories's PE ratio is 30.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.68x versus 4.47x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.5.68x 39.34x $5.3B $670M ABTAbbott Laboratories4.47x 30.59x $11.5B $1.8B
-
Which has Higher Returns BSX or GMED?
Globus Medical, Inc. has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 15.47%. Boston Scientific Corp.'s return on equity of 12.55% beat Globus Medical, Inc.'s return on equity of 10.08%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.68.5% $0.45 $36.4B GMEDGlobus Medical, Inc.63.28% $0.88 $4.5B -
What do Analysts Say About BSX or GMED?
Boston Scientific Corp. has a consensus price target of $104.78, signalling upside risk potential of 37.36%. On the other hand Globus Medical, Inc. has an analysts' consensus of $107.17 which suggests that it could grow by 18.88%. Given that Boston Scientific Corp. has higher upside potential than Globus Medical, Inc., analysts believe Boston Scientific Corp. is more attractive than Globus Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.25 0 0 GMEDGlobus Medical, Inc.6 4 0 -
Is BSX or GMED More Risky?
Boston Scientific Corp. has a beta of 0.666, which suggesting that the stock is 33.441% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.056, suggesting its more volatile than the S&P 500 by 5.621%.
-
Which is a Better Dividend Stock BSX or GMED?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSX or GMED?
Boston Scientific Corp. quarterly revenues are $5.3B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Boston Scientific Corp.'s net income of $670M is higher than Globus Medical, Inc.'s net income of $119M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 39.34x while Globus Medical, Inc.'s PE ratio is 29.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.68x versus 4.49x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.5.68x 39.34x $5.3B $670M GMEDGlobus Medical, Inc.4.49x 29.13x $769M $119M
-
Which has Higher Returns BSX or ISRG?
Intuitive Surgical, Inc. has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 27.89%. Boston Scientific Corp.'s return on equity of 12.55% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.68.5% $0.45 $36.4B ISRGIntuitive Surgical, Inc.66.41% $2.21 $18.1B -
What do Analysts Say About BSX or ISRG?
Boston Scientific Corp. has a consensus price target of $104.78, signalling upside risk potential of 37.36%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 22.18%. Given that Boston Scientific Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Boston Scientific Corp. is more attractive than Intuitive Surgical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.25 0 0 ISRGIntuitive Surgical, Inc.16 10 1 -
Is BSX or ISRG More Risky?
Boston Scientific Corp. has a beta of 0.666, which suggesting that the stock is 33.441% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.
-
Which is a Better Dividend Stock BSX or ISRG?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSX or ISRG?
Boston Scientific Corp. quarterly revenues are $5.3B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Boston Scientific Corp.'s net income of $670M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 39.34x while Intuitive Surgical, Inc.'s PE ratio is 63.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.68x versus 18.05x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.5.68x 39.34x $5.3B $670M ISRGIntuitive Surgical, Inc.18.05x 63.58x $2.9B $799.5M
-
Which has Higher Returns BSX or RMD?
ResMed, Inc. has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 27.59%. Boston Scientific Corp.'s return on equity of 12.55% beat ResMed, Inc.'s return on equity of 25.44%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.68.5% $0.45 $36.4B RMDResMed, Inc.60.93% $2.68 $7.2B -
What do Analysts Say About BSX or RMD?
Boston Scientific Corp. has a consensus price target of $104.78, signalling upside risk potential of 37.36%. On the other hand ResMed, Inc. has an analysts' consensus of $297.47 which suggests that it could grow by 14.89%. Given that Boston Scientific Corp. has higher upside potential than ResMed, Inc., analysts believe Boston Scientific Corp. is more attractive than ResMed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.25 0 0 RMDResMed, Inc.8 7 1 -
Is BSX or RMD More Risky?
Boston Scientific Corp. has a beta of 0.666, which suggesting that the stock is 33.441% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.099%.
-
Which is a Better Dividend Stock BSX or RMD?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.60 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BSX or RMD?
Boston Scientific Corp. quarterly revenues are $5.3B, which are larger than ResMed, Inc. quarterly revenues of $1.4B. Boston Scientific Corp.'s net income of $670M is higher than ResMed, Inc.'s net income of $392.6M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 39.34x while ResMed, Inc.'s PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.68x versus 7.04x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.5.68x 39.34x $5.3B $670M RMDResMed, Inc.7.04x 25.59x $1.4B $392.6M
-
Which has Higher Returns BSX or SYK?
Stryker Corp. has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 11.84%. Boston Scientific Corp.'s return on equity of 12.55% beat Stryker Corp.'s return on equity of 15.17%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.68.5% $0.45 $36.4B SYKStryker Corp.62.81% $2.20 $38.8B -
What do Analysts Say About BSX or SYK?
Boston Scientific Corp. has a consensus price target of $104.78, signalling upside risk potential of 37.36%. On the other hand Stryker Corp. has an analysts' consensus of $424.40 which suggests that it could grow by 12.48%. Given that Boston Scientific Corp. has higher upside potential than Stryker Corp., analysts believe Boston Scientific Corp. is more attractive than Stryker Corp..
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.25 0 0 SYKStryker Corp.12 8 0 -
Is BSX or SYK More Risky?
Boston Scientific Corp. has a beta of 0.666, which suggesting that the stock is 33.441% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.679%.
-
Which is a Better Dividend Stock BSX or SYK?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.88 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BSX or SYK?
Boston Scientific Corp. quarterly revenues are $5.3B, which are smaller than Stryker Corp. quarterly revenues of $7.2B. Boston Scientific Corp.'s net income of $670M is lower than Stryker Corp.'s net income of $849M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 39.34x while Stryker Corp.'s PE ratio is 44.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.68x versus 5.81x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.5.68x 39.34x $5.3B $670M SYKStryker Corp.5.81x 44.93x $7.2B $849M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 4.19% over the past day.
Sell
37
ACLS alert for Feb 19
Axcelis Technologies, Inc. [ACLS] is down 1.71% over the past day.
